BRAIN CANCER

HER2 Breast Cancer

BREAST CANCER

Bladder Cancer

Prostate Cancer

Renal Cell Carcinoma

GENITOURINARY CANCERS

Liquid Biopsies

GENOMIC TESTING

Colorectal Cancer

GIST

Gastric Cancer

GI CANCERS

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

GYNECOLOGIC CANCERS

HEAD & NECK CANCERS

Bone Marrow & Stem Cell Transplant

HEMATOLOGY

CAR T-Cell Therapy

IMMUNOTHERAPY

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

LEUKEMIAS

Biomarker-Driven Lung Cancer

EGFR+ Lung Cancer

MET-Targeted Therapy

Small Cell Lung Cancer

LUNG CANCER

DLBCL

Follicular Lymphoma

Mantle Cell Lymphoma

LYMPHOMAS

MPNs

MULTIPLE MYELOMA

NTRK GENE FUSIONS

SARCOMA

Melanoma

SKIN CANCERS

THYROID CANCERS

NEWS

Special Reports

All News

FDA Briefs

Oncology Icons

The Targeted Pulse

Voices from the Field

CONFERENCES

Conference Coverage

Conference Listing

Data Dialogue with the Oncology Brothers

MEDIA

All Videos

Case-Based Peer Perspectives

Evolving Paradigms in Oncology

Expert Perspective Virtual Tumor Board

Interviews

Investigator Perspectives

Medical World News

Pivotal Practice Views with the Oncology Brothers

Podcasts

Speaking Out

PUBLICATIONS

All Publications

Evolving Paradigms

Peers & Perspectives in Oncology

Targeted Therapies in Oncology

CASE-BASED ROUNDTABLE

PARTNERS

RESOURCES

CME/CE

Clinical Trials

Events

Precision Medicine Perspectives

Press Releases

Treatment Resources

SUBSCRIBE

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.

About Us

Advertise

Contact Us

CureToday.com

CancerNetwork.com

OncLive.com

OncNursingNews.com

Do Not Sell My Information

Privacy

Terms & Conditions

Editorial Board

Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Facebook

Linkedin

YouTube

Instagram

Featured Clinical Focus

BTK Inhibitors: In-Focus

Bone Marrow & SCT

EGFR-Positive Lung Cancer

Lung Cancer

Multiple Myeloma

Thyroid Cancers

Clinical Focus

Brain Cancer

Breast Cancer

Gastrointestinal Cancer

Genitourinary Cancers

Gynecologic Cancers

Head & Neck Cancers

Hematology

Leukemias

Lymphomas

Sarcoma

Skin Cancers

Spotlight

1rem

View

Chronic GvHD MUD HCT for AML Despite Tacrolimus/Methotrexate Prophylaxis

Case Based Peer Perspectives

Quality of Life Impact

Videos

Dr. Cutler discusses the management of chronic graft-versus-host disease (cGvHD) in a 48-year-old man who developed cGvHD after undergoing a matched unrelated donor (MUD) hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML), despite receiving tacrolimus and methotrexate as prophylaxis.

Exploring the main treatment goals and current first-line and second-line treatment options for patients with chronic GvHD.

Treatment Goals and Options for Chronic GvHD

Discussing the appropriateness of the initial therapy based on the NCCN guidelines for the given patient case.

Appropriateness of Initial Therapy for Chronic GvHD

Examining the efficacy and safety findings from recent studies on ibrutinib, ruxolitinib, and Belumosudil for chronic GvHD, and their implications for treatment choices.

Efficacy and Safety of Emerging Therapies

Discussing the key safety issues observed with ruxolitinib treatment in the REACH-3 trial and evaluating the risk/benefit profile for patients with steroid-refractory chronic GvHD.

Safety Profile of GVHD Treatment Options

Exploring general principles and practices for monitoring and mitigating adverse events in patients with chronic GvHD treated with systemic agents, and determining when dose modification or treatment discontinuation is warranted.

Monitoring and Mitigating Adverse Events

Discussing how various treatments for chronic GvHD impact quality of life in terms of disease response and side effects.

Evaluating the significance of the AGAVE-201 trial results for axatilimab in refractory chronic GvHD and key factors to consider when assessing the data.

Axatilimab Trial Results

Discussing perspectives on the future landscape of chronic GvHD management, including limitations of current targeted treatment options and emerging research of interest.

Future Landscape of cGvHD Management

Quality of Life Impact

EP: 1.Treatment Goals and Options for Chronic GvHD

EP: 2.Appropriateness of Initial Therapy for Chronic GvHD

EP: 3.Efficacy and Safety of Emerging Therapies

EP: 4.Safety Profile of GVHD Treatment Options

EP: 5.Monitoring and Mitigating Adverse Events

EP: 6.Quality of Life Impact

EP: 7.Axatilimab Trial Results

EP: 8.Future Landscape of cGvHD Management

Newsletter